Trial Profile
A dose-finding and safety phase I trial of Fraunhofer CMB's plant-derived influenza H5N1 vaccine in healthy volunteers.
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 10 Dec 2010
Price :
$35
*
At a glance
- Drugs Influenza A virus vaccine-H5N1 (Primary)
- Indications Influenza A virus infections
- Focus Adverse reactions
- Sponsors Fraunhofer USA Center for Molecular Biotechnology
- 10 Dec 2010 New trial record
- 07 Dec 2010 This trial has been initiated, according to a Fraunhofer USA CMB media release.